Immunodominant glycoprotein 41 epitope identified by seroreactivity in HIV type 1-infected individuals

AIDS Research and Human Retroviruses

Volumn 12, Issue 8, 1996, Pages 705-713

  Calarota, Sandra ^a,b   Jansson, Marianne ^b   Levi, Michael ^c   Broliden, Kristina ^c   Libonatti, Osvaldo ^a   Wigzell, Hans ^b   Wahren, Britta ^b,c  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ANTIBODY RESPONSE; ANTIGEN RECOGNITION; ARGENTINA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; MALE; PRIORITY JOURNAL; SWEDEN;

EID: 0029921050     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.705     Document Type: Article

References (29)

1. Lasky LA, Groopman JE, Fennie CW, Benz PM, Capon DJ, Dowbenko DJ, Nakamura GR, Nunes WM, Renz ME, and Berman PW: Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 1986;233:209-212.
2. Rusche JA, Javaherian K, McDanal C, Petro J, Lynn DL, Grimaila R, Langlois A, Gallo RC, Arthur LO, Fischinger PJ, Bolognesi DP, Putney SD, and Matthews TJ: Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci USA 1988;85:3198-3202.
3. Ho DD, Sarnhgadharan MG, Hirsch MS, Schooley RT, Rota TR, Kennedy RC, Chanh TC, and Sato VL: Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol 1987;61:2024-2028.
4. Chanh TC, Dreesman GR, Kanda P, Linette GP, Sparrow JT, Ho DD, and Kennedy RC: Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J 1986;5:3065-3071.
5. Fung MSC, Sun CRY, Gordon WL, Liou RS, Chang TW, Sun WNC, Daar ES, and Ho DD: Identification and characterization of a neutralizing site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol 1992;66:848-856.
6. McKeating JA, Shotton C, Cordell J, Graham S, Balfe P, Sullivan N, Charles M, Page M, Bolmstedt A, Olofsson S, Kayman SC, Wu Z, Pinter A, Dean C, Sodroski J, and Weiss RA: Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and the second variable domains of human immunodeficiency virus type 1 gp120. J Virol 1993;67:4932-4944.
7. Palker TJ, Clark ME, Langlois AJ, Matthews TJ, Weinhold KJ, Randall RR, Bolognesi DP, and Haynes BF: Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc Natl Acad Sci USA 1988;85:1932-1936.
8. Goudsmit J, Debouck C, Meloen RH, Smit L, Bakker M, Asher DM, Wolff AV, Gibbs CJJ, and Gajdusek DC: Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc Natl Acad Sci USA 1988;85:4478-4482.
9. Javaherian K, Langlois AJ, McDanal C, Ross KL, Eckler LI, Jellis CL, Profy AT, Rusche JR, Bolognesi DP, Putney SD, and Matthews TJ: Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc Natl Acad Sci USA 1989;86:6768-6772.
10. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dreesman GR, Boswell RN, Shadduck P, Holley LH, Karplus M, Bolognesi DP, Matthews TJ, Emini EA, and Putney SD: Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science 1990;249:932-935.
11. Åkerblom L, Hinkula J, Broliden PA, Mäkitalo B, Fridberger T, Rosen J, Villacres-Eriksson M, Morein B, and Wahren B: Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS 1990;4:953-960.
12. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, Koenig S, and Zolla-Pazner S: Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol 1992;66:7538-7542.
13. Ho DD, McKeating JA, Li XL, Moudgil T, Daar ES, Sun NC, and Robinson JE: Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol 1991;65: 489-493.
14. Tilley SA, Honnen WJ, Racho ME, Hilgartner M, and Pinter A: A human monoclonal antibody against the CD4 binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity. Res Virol 1991;142:247-259.
15. Modrow S, Hahn BH, Shaw GM, Gallo RC, Wong-Staal F, and Wo H: Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: Prediction of antigenic epitopes in conserved and variable regions. J Virol 1987;61:570-578.
16. Broliden PA, von Gegerfelt A, Clapham P, Rosen J, Fenyö EM, Wahren B, and Broliden K: Identification of human neutralization-inducing regions of the human immunodeficiency virus type 1 envelope glycoproteins. Proc Natl Acad Sci USA 1992;89:461-465.
17. Buchacher A, Predl R, Tauer C, Purtscher M, Gruber G, Heider R, Steindl F, Trkola A, Jungbauer A, and Katinger H: Human monoclonal antibodies against gp41 and gp 120 as potential agent for passive immunization. In: Vaccines 92: Modern Approaches to New Vaccines Including Prevention of AIDS (Brown F, et al., eds.). Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1992, pp. 191-195.
18. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Punscher M, Gruber G, Tauer C, Steindl F, Jungbauer A, and Katinger H: Generation of human monoclonal antibodies against HIV-1 proteins, electrofusion and EBV-transformation for PBL-immortalization. AIDS Res Hum Retroviruses 1994;10:359-369.
19. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Rüker F, and Katinger H: A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-6647.
20. Muster T, Guinea R, Trkola A, Punscher M, Klima A, Steindl F, Palese P, and Katinger H: Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J Virol 1994;68:4031-4034.
21. Sällberg M, Rudén U, Magnius LO, Norrby E, and Wahren B: Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett 1991;30:59-68.
22. Albert J, Abrahamsson B, Nagy K, Aurelius E, Gaines H, Nyström G, and Fenyö EM: Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. AIDS 1990;4:107-112.
23. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, Muggiasca L, and Fenyö EM: Mother-to-child transmission of human immunodeficiency virus type 1: Correlation with neutralizing antibodies against primary isolates. J Infect Dis 1993;168:207-210.
24. Sundqvist VA, Albert J, Ohlsson E, Hinkula J, Fenyö EM, and Wahren B: Human immunodeficiency virus type-1 p24 production and antigenic variation in tissue culture with various growth characteristics. J Med Virol 1989;29:170-175.
25. Broliden PA, Ljunggren K, Hinkula J, Norrby E, Åkerblom L, and Wahren B: A monoclonal antibody to HIV-1 mediating cellular cytotoxicity (ADCC) and neutralisation. J Virol 1990;64:936-940.
26. Gomez Carrillo M, Piccardo C, and Libonatti O: Molecular analysis of the principal neutralization epitope (V3 loop) of human immunodeficiency virus type 1 in Argentina. Rev Arg Microbiol 1992;24:91-101.
27. Warren RQ, Wong MT, Melcher GP, Blatt SP, Cahn P, Perez H, Zapiola I, Bouzas MB, Muchinik G, Anderson SA, and Kennedy RC: Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates. J Clin Microbiol 1995;33:481-483.
28. Conley AJ, Kessler JA, Boots LJ, Tung JS, Arnold BA, Keller PM, Shaw AR, and Emini EA: Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc Natl Acad Sci USA 1994;91:3348-3352.
29. Neurath AR, Strick N, Lin K, and Jiang S: Multifaceted consequences of anti-gp41 monoclonal antibody 2F5 binding to HIV type 1 virions. AIDS Res Hum Retroviruses 1995;11:687-696.